If you made any changes in Pure these will be visible here soon.

Research Output

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

Lieverse, R. I. Y., Marcus, D., van der Wiel, A. M. A., Van Limbergen, E. J., Theys, J., Yaromina, A., Lambin, P. & Dubois, L. J., Jul 2020, In : Molecular oncology. 14, 7, p. 1555-1568 14 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access

Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer

Sanduleanu, S., van der Wiel, A. M. A., Lieverse, R. I. Y., Marcus, D., Ibrahim, A., Primakov, S., Wu, G., Theys, J., Yaromina, A., Dubois, L. J. & Lambin, P., May 2020, In : Cancers. 12, 5, 16 p., 1322.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A-M. C., Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., de Jong, M. C., Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., Pasquier, D. & 5 others, Boisselier, P., Yaromina, A., De Ruysscher, D., Dubois, L. J. & Lambin, P., 15 Jun 2020, In : BMC Cancer. 20, 1, 10 p., 557.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Will immunotherapy really change radiotherapy?

Lambin, P., Lieverse, R., Baumann, M. & Ebert, N., Dec 2019, In : Lancet oncology. 20, 12, p. 1642-1644 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review